Business Context and Reporting Period
Revelation Biosciences, Inc., a Delaware corporation, filed this Form 8-K on August 1, 2022, reporting events occurring on July 28, 2022. The company is an emerging growth company focused on program development.
Key Financial Metrics
This filing details a capital raise rather than operational financial results. Key metrics include:
- Net Proceeds: Approximately $4.4 million received after deducting offering expenses and placement agent fees.
- Offering Size: 8,333,334 shares of common stock and warrants to purchase an equal number of shares.
- Offering Price: $0.60 per share and associated warrant.
- Placement Agent Compensation: 7% cash fee of gross proceeds plus reimbursement of expenses and legal fees, plus 583,333 Placement Agent Warrants.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of the proceeds from this specific transaction.
Material Changes
The primary material change is the completion of a public offering on July 28, 2022. This transaction significantly increased the company's cash position through the issuance of new equity and warrants. The company entered into a Securities Purchase Agreement with institutional investors on July 25, 2022, to facilitate this offering.
Guidance, Outlook, and Risks
Use of Proceeds: Management intends to use the net proceeds for program development expenses and general corporate purposes.
Warrant Terms: Public warrants are exercisable immediately at $0.60 per share and expire five years from issuance. Placement Agent Warrants have an exercise price of $0.75 per share.
Risks and Contingencies: The filing notes that the exercise price of the warrants is subject to adjustment for stock splits, reverse splits, and similar capital transactions. No specific operational risks or contingencies were detailed in this specific report beyond standard agreement terms.
Investor Verification Checklist
- Verify the total number of outstanding shares post-offering to assess dilution impact.
- Confirm the exact amount of gross proceeds raised versus the $4.4 million net proceeds reported.
- Review the specific terms of the Placement Agent Warrants (583,333 shares at $0.75 exercise price) for potential future dilution.
- Monitor the company's cash burn rate relative to the $4.4 million raised to determine runway for program development.